Capricor Stock Tumbles After FDA Panel Rejects Evidence for Duchenne Cell Therapy
Capricor stock plunged after an FDA panel questioned Deramiocel's effectiveness in DMD despite published Phase 3 HOPE-3 trial results.
A group of government health experts said they weren't convinced Capricor's medicine works well enough for a serious muscle disease, even though the company's test results looked good. When experts doubt a company's main product, people worry the company might struggle, so its stock price dropped.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.